CN1465700A - Hepatitis c virus tunic protein E2 gene capable of being total length expressed in E. coli, its coding protein and use - Google Patents
Hepatitis c virus tunic protein E2 gene capable of being total length expressed in E. coli, its coding protein and use Download PDFInfo
- Publication number
- CN1465700A CN1465700A CNA021120897A CN02112089A CN1465700A CN 1465700 A CN1465700 A CN 1465700A CN A021120897 A CNA021120897 A CN A021120897A CN 02112089 A CN02112089 A CN 02112089A CN 1465700 A CN1465700 A CN 1465700A
- Authority
- CN
- China
- Prior art keywords
- expression
- hcv
- hepatitis
- protein
- pqe8
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 36
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 14
- 241000711549 Hepacivirus C Species 0.000 title claims abstract description 12
- 101710132593 Protein E2 Proteins 0.000 title abstract 3
- 241000588724 Escherichia coli Species 0.000 title description 4
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 title 1
- 208000005176 Hepatitis C Diseases 0.000 claims abstract description 11
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 238000003745 diagnosis Methods 0.000 claims abstract description 4
- 241000894006 Bacteria Species 0.000 claims description 24
- 101710091045 Envelope protein Proteins 0.000 claims description 23
- 101710188315 Protein X Proteins 0.000 claims description 23
- 230000000968 intestinal effect Effects 0.000 claims description 21
- 235000018102 proteins Nutrition 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 9
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 102100021696 Syncytin-1 Human genes 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 63
- 230000005847 immunogenicity Effects 0.000 abstract description 3
- 101710125507 Integrase/recombinase Proteins 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 abstract description 2
- 239000002775 capsule Substances 0.000 abstract 2
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000010367 cloning Methods 0.000 description 25
- 230000035772 mutation Effects 0.000 description 25
- 230000010363 phase shift Effects 0.000 description 25
- 102100034349 Integrase Human genes 0.000 description 22
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 20
- 150000001413 amino acids Chemical class 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 19
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 229940024606 amino acid Drugs 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 12
- 229910021529 ammonia Inorganic materials 0.000 description 10
- 230000008521 reorganization Effects 0.000 description 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 238000003119 immunoblot Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 208000006454 hepatitis Diseases 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 241000700618 Vaccinia virus Species 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000013016 damping Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 206010046865 Vaccinia virus infection Diseases 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 102220369447 c.1352G>A Human genes 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 102000008482 12E7 Antigen Human genes 0.000 description 1
- 108010020567 12E7 Antigen Proteins 0.000 description 1
- HHGYNJRJIINWAK-FXQIFTODSA-N Ala-Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N HHGYNJRJIINWAK-FXQIFTODSA-N 0.000 description 1
- 101710153593 Albumin A Proteins 0.000 description 1
- ZATRYQNPUHGXCU-DTWKUNHWSA-N Arg-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCCN=C(N)N)N)C(=O)O ZATRYQNPUHGXCU-DTWKUNHWSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- LJPIRKICOISLKN-WHFBIAKZSA-N Gly-Ala-Ser Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O LJPIRKICOISLKN-WHFBIAKZSA-N 0.000 description 1
- CCQOOWAONKGYKQ-BYPYZUCNSA-N Gly-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)CN CCQOOWAONKGYKQ-BYPYZUCNSA-N 0.000 description 1
- 101000666856 Homo sapiens Vasoactive intestinal polypeptide receptor 1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- KUHFPGIVBOCRMV-MNXVOIDGSA-N Ile-Gln-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)O)N KUHFPGIVBOCRMV-MNXVOIDGSA-N 0.000 description 1
- PTRKPHUGYULXPU-KKUMJFAQSA-N Leu-Phe-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O PTRKPHUGYULXPU-KKUMJFAQSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- VMVNCJDKFOQOHM-GUBZILKMSA-N Ser-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N VMVNCJDKFOQOHM-GUBZILKMSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- ABSXSJZNRAQDDI-KJEVXHAQSA-N Tyr-Val-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ABSXSJZNRAQDDI-KJEVXHAQSA-N 0.000 description 1
- PVPAOIGJYHVWBT-KKHAAJSZSA-N Val-Asn-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N)O PVPAOIGJYHVWBT-KKHAAJSZSA-N 0.000 description 1
- 102100038388 Vasoactive intestinal polypeptide receptor 1 Human genes 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- YVNQAIFQFWTPLQ-UHFFFAOYSA-O [4-[[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfophenyl)methyl]amino]-2-methylphenyl]methylidene]-3-methylcyclohexa-2,5-dien-1-ylidene]-ethyl-[(3-sulfophenyl)methyl]azanium Chemical compound C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=C1 YVNQAIFQFWTPLQ-UHFFFAOYSA-O 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108010091092 arginyl-glycyl-proline Proteins 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 102220369445 c.668T>C Human genes 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 102220023257 rs387907546 Human genes 0.000 description 1
- 102220023258 rs387907548 Human genes 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN02112089.7A CN1273482C (en) | 2002-06-14 | 2002-06-14 | Hepatitis C virus tunic protein E2 gene capable of being total length expressed in E. coli, its coding protein and use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN02112089.7A CN1273482C (en) | 2002-06-14 | 2002-06-14 | Hepatitis C virus tunic protein E2 gene capable of being total length expressed in E. coli, its coding protein and use |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1465700A true CN1465700A (en) | 2004-01-07 |
CN1273482C CN1273482C (en) | 2006-09-06 |
Family
ID=34141838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN02112089.7A Expired - Fee Related CN1273482C (en) | 2002-06-14 | 2002-06-14 | Hepatitis C virus tunic protein E2 gene capable of being total length expressed in E. coli, its coding protein and use |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1273482C (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100395339C (en) * | 2006-02-28 | 2008-06-18 | 中国人民解放军第二军医大学 | Method for expressing hepatitis C virus envelope protein E2 by mammal cell with high efficient secretion |
CN103435690A (en) * | 2013-09-13 | 2013-12-11 | 武汉大学 | DNA (deoxyribonucleic acid) vaccine of HCV (hepatitis C virus) and preparation method thereof |
CN104974246A (en) * | 2014-04-01 | 2015-10-14 | 中国科学院上海巴斯德研究所 | Total-human monoclonal antibody for neutralizing hepatitis C virus and application of total-human monoclonal antibody |
CN105330730A (en) * | 2014-07-29 | 2016-02-17 | 中国科学院上海巴斯德研究所 | Preparation and application of hepatitis C virus recombinant protein |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012016290A1 (en) * | 2010-08-04 | 2012-02-09 | The Macfarlane Burnet Institute For Medical Research And Public Health Ltd | Modified hepatitis c virus proteins |
-
2002
- 2002-06-14 CN CN02112089.7A patent/CN1273482C/en not_active Expired - Fee Related
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100395339C (en) * | 2006-02-28 | 2008-06-18 | 中国人民解放军第二军医大学 | Method for expressing hepatitis C virus envelope protein E2 by mammal cell with high efficient secretion |
CN103435690A (en) * | 2013-09-13 | 2013-12-11 | 武汉大学 | DNA (deoxyribonucleic acid) vaccine of HCV (hepatitis C virus) and preparation method thereof |
CN103435690B (en) * | 2013-09-13 | 2016-02-10 | 武汉大学 | DNA vaccination of a kind of hepatitis C virus and preparation method thereof |
CN104974246A (en) * | 2014-04-01 | 2015-10-14 | 中国科学院上海巴斯德研究所 | Total-human monoclonal antibody for neutralizing hepatitis C virus and application of total-human monoclonal antibody |
CN105330730A (en) * | 2014-07-29 | 2016-02-17 | 中国科学院上海巴斯德研究所 | Preparation and application of hepatitis C virus recombinant protein |
Also Published As
Publication number | Publication date |
---|---|
CN1273482C (en) | 2006-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040247617A1 (en) | Fusion antigen used as vaccine | |
CN106995488A (en) | The H1N1 influenza antigens of the width reactivity of calculation optimization | |
CN101062410A (en) | Genetic engineering vaccine of enterohemorrhagic escherichia coli 0157:H7 and the preparing method thereof | |
LiHua et al. | Evaluation of an outer membrane protein as a vaccine against Edwardsiella anguillarum in Japanese eels (Anguilla japonica) | |
CN100412088C (en) | Enzyme-linked immunosorbent test detecting reagent kit for non-structure protein of pig and cow foot and mouth disease virus | |
CN104628871B (en) | A kind of preparation for recombinating bursal disease protein engineering vaccine | |
EP3013852A1 (en) | Methods and compositions for dengue virus vaccines | |
Li et al. | The development of classical swine fever marker vaccines in recent years | |
CN1465700A (en) | Hepatitis c virus tunic protein E2 gene capable of being total length expressed in E. coli, its coding protein and use | |
Harasawa | Adventitious pestivirus RNA in live virus vaccines against bovine and swine diseases | |
AU718740B2 (en) | Polyvalent anti-dengue vaccine | |
CN107970444A (en) | Composite adjuvant and the vaccine containing the composite adjuvant | |
CN1176945C (en) | Plasmodium fused antigen and its preparing process and usage | |
KR101127926B1 (en) | Iridovirus antigenic peptide and vaccine comprising the same | |
CN100335636C (en) | Thioredoxin gene of Schistosoma japonicum (Chinese Mainland Strain) and its cloning expression method and application | |
CN1737147B (en) | Heat shock protein 65- multiple epitope hepatitis B virus core antigen recombinant protein (HSP65-HBcAg) | |
CN102212120A (en) | Salmonella paratyphi A PagC subunit vaccine and preparation method thereof | |
CN103361364A (en) | Eimeria tenella eIF3d gene and application thereof | |
CA2370278C (en) | Chimeric lyssavirus nucleic acids and polypeptides | |
CN101845084B (en) | Recombination polypeptide serving as group A streptococcic tetravalent vaccine protective antigen | |
CN1831009A (en) | Prawn white-spots syndrom virus (WSSV) membrane protein and its antibody | |
CN105727278B (en) | A kind of sore mouth virus recombinant protein antigen vaccine and preparation method thereof | |
EP1578791B1 (en) | Inclusion bodies for the oral vaccination of animals | |
CN1458168A (en) | Recombined pig influenza virus NP antigen, its preparing method and use in diagnosis | |
CN104497148B (en) | A kind of preparation for recombinating ubiquitination blue-ear disease vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI INST. OF LIFE SCIENCE, CAS Free format text: FORMER OWNER: INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY, SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CHINESE ACADEMY OF SCIENCES Effective date: 20090626 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20090626 Address after: No. 320, Yueyang Road, Shanghai Patentee after: SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CHINESE ACADEMY OF SCIENCES Address before: No. 320, Yueyang Road, Shanghai Patentee before: Institute of Biochemistry and cell biology, Shanghai Institute of life sciences, Chinese Academy of Sciences |
|
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Shenzhen Feipeng Biological Co.,Ltd. Assignor: SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CHINESE ACADEMY OF SCIENCES Contract fulfillment period: 2009.6.17 to 2014.6.17 Contract record no.: 2009310000125 Denomination of invention: Hepatitis c virus tunic protein E2 gene capable of being total length expressed in E. coli, its coding protein and use Granted publication date: 20060906 License type: Exclusive license Record date: 20090713 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.6.17 TO 2014.6.17; CHANGE OF CONTRACT Name of requester: SHENZHEN CITY FAPON BIOTECH CO., LTD. Effective date: 20090713 |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060906 Termination date: 20170614 |
|
CF01 | Termination of patent right due to non-payment of annual fee |